multiple-sclerosis

Novartis's multiple-sclerosis pill Gilenya won approval in Europe, accelerating the global rollout of a medicine that is already on the market in the U.S. and is expected to net more than $3 billion in annual sales.

Business Watch 2011

Currently, Teva Pharmaceutical Industries Ltd. and Sanofi-Aventis SA own the market's best-selling multiple-sclerosis drug, Copaxone, which had $3.3 billion in sales in 2010.

Novartis's MS Drug Gets Approval from EU Goran Mijuk 2011

The company sees branded-drug sales of about $8.2 billion, including an estimated $3.8 billion for multiple-sclerosis drug Copaxone, $550 million for leukemia drug Treanda, and women's-health-product sales of $525 million.

Teva Sees Sales, Profit Up In 2012 Peter Loftus 2011

The U.K. health-care watchdog, in draft guidance, Friday recommended against reimbursing for Novartis AG's multiple-sclerosis medicine Gilenya because of uncertainties over the drug's clinical effectiveness for certain patients.

Novartis' MS Pill Questioned by U.K. Regulator Goran Mijuk 2011

Part of the steep rise was also due to the recent full acquisition of Alcon as well as strong sales of drugs such as eye medicine Lucentis and recently approved multiple-sclerosis pill Gilenya.

Novartis Posts 6% Profit Drop on Forex, Financing Goran Mijuk 2011

Merck recently suffered a major blow when a European Union panel confirmed its negative opinion on its multiple sclerosis pill Cladribine, which was once set to be the first multiple-sclerosis pill worldwide and had the potential for peak sales of more than €1 billion.

Germany's Merck Posts 73% Gain in Net Profit Natascha Divac 2011

During the quarter, there was a 31% jump in sales of flagship multiple-sclerosis treatment Tysabri, which is sold by Elan and U.S.-based partner Biogen Idec Inc., to $389 million.

Elan's Loss Narrows Sten Stovall 2011

Europe's drug regulator is reviewing the "benefits and risks" of Novartis's multiple-sclerosis drug Gilenya and recommended doctors closely monitor the hearts of patients after they have been given the first dose of the drug.

What's News 2012

Merck's confidence in 2011 may in part be due to strong fourth-quarter sales of its key multiple-sclerosis product Rebif, Mr. Frericks said.

Germany's Merck Posts 73% Gain in Net Profit Natascha Divac 2011

Most of the payments are related to the approval and sales milestones of multiple-sclerosis drug Lemtrada, which is expected to have late-stage clinical data later this year.

Genzyme's CEO Could Get Big Payment Thomas Gryta 2011